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1. Introduction  
It has been almost half a century since Leo Kanner first described the clinical phenotype 
associated with Autism1. Since Kanner's descriptions, much effort has been devoted to 
understanding and identifying the factors which may contribute to Autism. It was not until 
the early 80’s that compelling evidence started to accumulate suggesting that Autism is a 
disorder of abnormal brain development. It is now generally accepted that both genetic and 
environmental factors are implicated in the etiology of this intriguing condition. In the 
current chapter, we will focus on the role of genetic factors involved in the pathogenesis of 
Autism. While multiple hypotheses have been proposed to account for the genetic origin of 
Autism, some have received more empirical support than others. While it is likely that more 
than one genetic mechanisms is involved in the pathogenesis of this disorder, this chapter 
will focus on a recent hypothesis implicating de novo mutations in synaptic genes. This 
hypothesis is based on the proposition that rare, highly penetrant mutations affecting any of 
many different genes which code for synaptic molecules, and which are specific to single 
families, predispose to Autism. Empirical lines of evidence for this hypothesis will be 
presented, along with examples, some of which are derived from work by our group.  
1.1 The role of genetics in autism 
Over the last two decades many studies aimed at identifying the genetic causes of Autism 
have shown that genetic factors play a predominant role in the genesis of this disorder. 
Twin studies predict that the heritability (i.e. the degree to which a given trait is controlled 
by inheritance) of Autism is between 70-90% (Bailey et al., 1995; Marco & Skuse, 2006; 
Lichtenstein et al., 2010). The relatively low concordance rate in dizygotic twins, the sharp 
decrease in recurrence risk of Autism in second- and third-degree relatives of autistic 
subjects (0.18% and 0.12% respectively) as well as a low risk in first-degree relatives of 
autistic subjects (3-7%) (Chakrabarti & Fombonne, 2001; Muhle et al., 2004) predicts two 
different genetic scenarios: 1) Autism could be explained by the co-inheritance in one 
individual of multiple disease-predisposing alleles, each with a small but additive effect, 
resulting in disease, or 2) by de novo mutations (i.e. not inherited from either parent). The 
first scenario is a polygenic inheritance, where the effect of multiple risk genes acting 
additively or multiplicatively results in disease. The second, very recently considered for 
Autism, argues that a fraction of the cases would result from incompletely penetrant new 
                                                 
1 In this chapter the term Autism refers to the autism spectrum disorders which include Autism 
disorder, Asperger syndrome and Pervasive developmental disorder not otherwise specified  
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mutations or de novo mutations, such that only identical twins would share the genetic 
predisposition to Autism, hence the much higher monozygotic concordance than dizygotic 
concordance. Familial aggregation studies demonstrate that the risk of developing Autism is 
greater in offspring than in the parents. There are many possible explanations, one of which 
is that new mutations cause a fraction of Autism cases.  
Dozens of genome-wide genetic linkage studies have been conducted in Autism kindred, 
identifying genetic signals of various significance levels on almost every arm of every 
human chromosome. There are few instances of consistent replication of linkage to any one 
site. Fine-mapping of these loci has been difficult, mainly because of genetic heterogeneity, 
so researchers have frequently opted to look at candidate genes directly based on the 
linkage results and/or on relevant gene functions. Association studies have also been used 
to search for genes in Autism. Although, in general, most studies have not been replicated, a 
few have been yielding a crop of possible susceptibility genes. Although the few replicated 
positive association studies are promising, it is surprising that no causative mutations or 
sequence variants have been identified in any of the loci associated with the disorder. In the 
absence of such mutations, the role of these genes in Autism remains unproven.  
A number of genes have been strongly associated with Autism. For example, the X-linked 
neuroligin genes, NLGN3 and NLGN4, two synaptic molecules, have been found to be 
associated with Autism. In the original report, two families with affected brothers (one with 
autism disorder and the other with Asperger syndrome) have a frameshifting and a 
missense mutation within the coding region of NLGN4 and NLGN3, respectively (Jamain et 
al., 2003). Interestingly, both were new mutations that occurred in the mother of the affected 
brothers. Other mutations have since been described in these genes further supporting their 
role in the pathogenesis of Autism. NLGN3 and NLGN4 belong to the neuroligin family of 
postsynaptic cell adhesion molecules that are widely expressed in the brain (Philibert et al., 
2000). The products of these genes are involved in late steps of synaptogenesis, mediating 
the specific recruitment of pre- and postsynaptic proteins to the site of initial synaptic 
contact. Two independent studies have shown in vitro that the frameshifting and the 
missense mutations described in humans alter the formation of presynaptic terminals (Chih 
et al., 2004; Comoletti et al., 2004). Since this discovery, mutations in other genes have been 
linked to Autism (discussed below). These findings support our hypothesis, which will be 
discussed in section below, that Autism is mainly a synaptic disorder largely caused by de 
novo mutations in synaptic genes. 
2. The concept of “de novo” mutations 
Recent studies on the direct measurement of human mutation rate have revealed that in any 
single conceptus there is approximately 1.1 x 10-8 (0.76 x 10-8 to 2.2 x 10-8) mutation per base per 
generation (Awadalla et al., 2010; Lynch, 2010; Roach et al., 2010). A newborn is thought to 
have acquired about sixty new mutations in his/her genome. Among these, approximately 
0.86 new deleterious mutation will lead to an altered amino acid, which corresponds to an 
average of about 1 new coding mutation per conceptus (Eyre-Walker & Keightley, 1999; 
Giannelli et al., 1999; Crow, 2000). De novo or spontaneous germline mutations can lead to 
serious clinical consequences, such as a disease, when affecting critical genes. 
2.1 Common disease and common variants  
Classical linkage and association studies, as mentioned earlier, have largely failed to identify 
predisposing genes for Autism as well as a number of other psychiatric disorders. The main 
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reason for this lack of success is likely to be allelic and non-allelic genetic heterogeneity, 
with dozens to perhaps hundreds of genes predisposing to Autism, with each gene having 
many allelic variants. Such heterogeneity would require an enormous sample size to detect 
predisposing genes using population genetic approaches. It is likely that this heterogeneity 
results mostly from our limited ability to sub-phenotype brain disorders, particularly 
behavioural disabilities. The diagnosis of most psychiatric disorders remains largely based 
on clinical criteria, which define broad categories of dysfunction that may or may not be 
biologically linked. To date, there is no consistent, biologically validated method for 
defining these sub-phenotypes. Simply stated, Autism, as currently defined, probably result 
from so many different genes and alleles that classical genetic methods will prove inefficient 
in the identification of susceptibility genes for this disorder. 
The hypothesis that a common disease may be caused by common variants was the 
favoured model for the genetic architecture of Autism until recently. Indeed, the 
constellation of published association studies reflects the widespread belief of the 
involvement of common variants in Autism. This hypothesis was appealing to many 
investigators since the common variants should be identifiable using methods such as 
linkage disequilibrium (Reich & Lander, 2001). Unfortunately, there are very few examples 
to support this hypothesis, particularly for brain disorders. Clinicians argue that Autism is a 
highly heterogeneous group of disorders, and none of them can be explained by single or 
even a few common variants. If this were the case, the plethora of genetic studies performed 
over the years should already have identified some of these variants. The widely distributed 
linkage and association positive signals scattered all over the genome rejects the existence of 
one or a few major predisposing common variants in this disorder. Furthermore, the few 
genes that have been found to definitely predispose to Autism explain only a small fraction 
of cases. This is not to say that some common variants will not be found for some 
predisposing genes, but this mechanism is unlikely to explain all the genetics of this 
condition.  
It has recently been recognized that many complex disorders may result from a mix of 
common and rare variants. Let us consider breast cancer as an example (Nathanson et al., 
2001): BRCA1 and BRCA2 genes contribute to a relatively common genetic disorder, but 
have many different rare mutations, even in a founder population (the Ashkenazim). For a 
complex trait such as Autism, the occurrence of many rare variants in many different 
disease predisposing genes seems to better predict the genetic architecture of the disorders 
(Pritchard, 2001; Pritchard & Cox, 2002; Smith & Lusis, 2002).  
As a final point on the common disease common variant hypothesis, most studies looking at 
disease-causative mutations for Autism report mutations that are not recurrent, i.e. not 
observed more than once and specific to one individual. Again this suggests that mutations 
at many different loci may contribute to Autism, a result consistent with the failure to find 
common heritable variants with a major effect on disease risk. Lack of recurrence of 
mutations may in fact reflect the possibility that autistic traits can result from many different 
genetic defects. 
2.2 Rare variants and new mutations 
While not all amino acid substitutions will be deleterious, a significant fraction will be and 
may lead to disease. Therefore, for a disorder that may result from dysfunction in any one of 
hundreds of different genes, new mutations may be responsible for a significant fraction of 
cases. For example, should dysfunction in any of 100 different genes potentially lead to 
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Autism, and assuming amino acid changes lead to gene dysfunction in one fifth of instances, 
new mutations could cause Autism in one case out of 1,000 births, which would correspond 
to over 10% of cases based on the overall population incidence.  
Looking at simple Mendelian traits, we can see that new mutations are common. For 
example, 1 in 6,000 live births harbour a novel mutation causing neurofibromatosis type 1  
(Stephens et al., 1992; Grimm et al., 1994; Hudson et al., 1997). The frequency of new point 
mutations in Duchenne Muscular Dystrophy is similar, 1 in 10,500 live births (Grimm et al., 
1994). One can argue that these are large genes, allowing for high mutation rate.  
Nonetheless, these are surprisingly high numbers of novel deleterious mutations. Let us 
consider Rett syndrome, which is closely related to Autism, and results from mutations in 
the relatively small MECP2 gene (4 exons, 498 amino acids). The incidence of Rett syndrome 
is one in 10,000-15,000 females. Because 99-99.5% of all cases are sporadic with new 
mutations, this represents a new mutation rate of one in 5,000-7,500 live births for this small 
gene of 498 amino acids (Hagberg, 1985; Hagberg & Hagberg, 1997; Van den Veyver & 
Zoghbi, 2001). This example clearly shows that, for neurodevelopmental disorders, new 
mutations can act dominantly and can occur with a high enough frequency to explain the 
relatively high incidence of Autism. A high rate of new mutations can in part explain why 
genetic studies have so far failed to identify many Autism genes, and why diseases have 
been identified for a mere 3% of genes in the human genome. Mutations in genes leading to 
severe outcome where there is a strong negative selection against the phenotype, such as 
lethality in embryonic stages or reduced reproductive fitness, will not be transmitted to 
multiple family members, and therefore will not be detected by linkage gene mapping.  
3. The role of de novo mutation in autism 
Though we predict that de novo mutations will be a frequent cause of Autism, we do not 
think that it will be the only genetic explanation. The alternative genetic hypothesis for 
complex traits, mentioned previously, predicts that disease results from a combination or 
pattern of genotypes at different susceptibility loci. In recent years, statisticians have 
developed analytical methods that capture contributions from multiple susceptibility loci, 
and provide evidence for the localization of disease genes on human chromosomes (Sherriff 
& Ott, 2001; Hoh & Ott, 2003; Carlson et al., 2004). However, such analyses are very complex 
and yield few successful examples, even considering the simplest scenarios (Tiret et al., 
1994; Bolk et al., 2000; Zetterberg et al., 2003). It seems that genome-wide searches using 
realistic sample sizes may not have the power to detect potential multi-gene interactions. 
The existence of new mutations, which contribute to this heterogeneity, makes classical 
genetic approaches even more difficult. Thus, the failure of conventional linkage and 
genome-wide association studies to identify but a few causative Autism genes is most likely 
due to two main confounding factors: phenotypic and genetic heterogeneity. Phenotypic 
heterogeneity is due to the inability to distinguish closely related clinical subtypes in the 
autism spectrum of behavioural disturbances. Genetic heterogeneity refers to fact that many 
different genes (and/or alleles of the same genes) lead to the same phenotype.  
3.1 Monozygotic and dizygotic concordance  
De novo mutations in identical twins would result in their sharing the same genetic 
predisposition to Autism. These alleles would be highly but not completely penetrant; hence 
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the high monozygotic concordance and the low dizygotic concordance, as in the latter case 
the unaffected twin would not share the novel disease predisposing allele. Instances of non-
penetrance would explain the fact that monozygotic twin concordance is not 100%. A de 
novo or spontaneous mutation can arise from different mechanisms and in different periods 
in the development of an individual. This kind of mutation can occur in the gametes (sperm 
or eggs), very early in the developing foetus or later in life as observed in cancer.  The partial 
phenotypic concordance in monozygotic twin could also be in part explained by the 
occurrence of a de novo mutation early in the development of one twin, but not the other.  
3.2 Reduced reproductive fitness  
In the general population, the mutational load can be thought of as a balance between 
selection against a deleterious gene and its acquisition of new mutations. Lower rates of 
reproduction constitute a negative selection factor that should reduce the number of mutant 
alleles in the population, ultimately leading to decreased disease prevalence. These selective 
pressures tend to be of different intensity in different environments. In the case of Autism, 
only rarely do individuals with Autism have children, particularly the more severely 
affected individuals (Nicolson & Szatmari, 2003). Thus, Autism has a lower reproductive 
fitness (which is the ability to pass on genes by having offspring) due to an early age of 
onset and severely impaired cognitive and social functions. This observation should 
influence the disorders incidence and prevalence; but this is not what we observe. Autism 
incidence and prevalence seems to be relatively constant worldwide..  
Studies of monogenic diseases2 indicate that rare diseases with strong negative selection 
generally exhibit very large allelic diversity, hence many different mutations (Smith & Lusis, 
2002). One exception to this pattern of high allelic diversity occurs when disease alleles also 
provide protection from negative environmental selective pressures. One example is the 
thalassemias, which confer resistance to malaria. Once arisen, the strong positive selective 
pressure conferred by these alleles allowed their relatively rapid spread through a specific 
population. However, such phenomena are usually regional, in response to specific regional 
environmental pressures. There are no examples of such phenomena occurring with equal 
strength in all cultural and geographical parts of the world, which needs to be the case to 
have a uniform incidence of Autism throughout the world. De novo mutations could explain 
this relatively uniform high incidence of disease, as new disease predisposing alleles will 
continually be introduced at a similar rate in all parts of the world. 
3.3 Effects of paternal age 
The male-to-female ratio of de novo mutations is estimated at about 4–6:1, presumably due to 
a higher number of germ-cell divisions with age in males(Crow, 2000). Therefore, one would 
predict that de novo mutations would more frequently come from males, particularly older 
men (Li et al., 2002).  At the genetic level, increased risk for a disease with increasing 
paternal age can be explained by spermatogonial stem cell divisions that occur over the 
lifetime of males contributing to higher mutational rates in the sperm of older men. A higher 
paternal origin of de novo mutations has been shown for many diseases, including Apert 
syndrome (Moloney et al., 1996), Crouzon syndrome (Glaser et al., 2000), Multiple endocrine 
neoplasia type II (Carlson et al., 1994) and neurofibromatosis type 1  (Jadayel et al., 1990).  
                                                 
2 Disorders caused by the inheritance of a single defective gene 
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Rett syndrome, a neurodevelopmental disease closely related to Autism, results almost 
entirely from new mutations which are exclusively of paternal origin (Girard et al., 2001; 
Trappe et al., 2001). A role for de novo mutations in Autism would predict that the incidence 
of disease should increase with increasing paternal age. Indeed, multiple recent studies 
reported advancing paternal age as a significant risk factor for Autism (Miller, 2006; Cantor 
et al., 2007; Croen et al., 2007; Puleo et al., 2008). Some authors have predicted a high 
incidence of male-derived novel mutations in many mental disorders (Preuss et al., 2004). 
Similar observation has been reported for schizophrenia (Malaspina et al., 2001) and  
intellectual disabilities (Malaspina et al., 2005), two conditions phenotypically related to 
Autism. These observations provide strong evidence that accumulation of de novo mutations 
in paternal sperm contributes to the overall risk of Autism. 
3.4 Worldwide incidence  
Data from a worldwide amalgam of studies show that the incidence of Autism has been 
maintained at a constant, relatively high prevalence in the worldwide population across a 
wide range of cultures and countries (McDonald & Paul, 2010). This occurs despite a strong 
negative selection against this condition. Indeed and with the exception of variants which 
date back to speciation, one would expect that common variants would result in a detectable 
uneven disease incidence across different populations due to migration, different 
population growth and isolation. This is not the case for Autism. In addition, this is not 
what one would predict in diseases with reduced reproductive fitness like Autism, unless 
there was a high new mutation rate. These observations emphasize the importance of de 
novo mutations in the pathogenicity of Autism.  
Taken together, the high prevalence, the high monozygotic twin concordance, the predicted 
high level of allelic and non-allelic genetic heterogeneity, the uniform worldwide high 
incidence despite significantly reduced reproductive fitness, constitute evidences that 
Autism may result at least in part, from de novo mutations.  
4. De novo mutations in genes associated with autism  
The fact that a growing number of studies, several from our group, report the association of 
rare genetic variants with Autism constitutes strong evidence for the de novo hypothesis. 
Indeed, among causal genes identified for Autism, Rett syndrome and intellectual disability 
(three closely related disorders), the predisposing mutations, whether they be copy number 
variations, insertions/deletions or point mutations, are very frequently of de novo origin. A 
good example of such a gene is SHANK3 encoding a synaptic scaffolding protein. Two of 
the first three mutations reported in the first manuscript linking SHANK3 to Autism were 
actually of de novo origin; one a deletion of the terminal 22q13 and the other a G insertion 
leading to a frameshift that was carried by two affected brothers (Durand et al., 2007). None 
of these mutations were found in the parents. Many subsequent reports on mutation 
screening of SHANK3 gene in Autim also find novel de novo mutations (Moessner et al., 
2007; Gauthier et al., 2009). Other examples, such as the neuroligins genes, NLGN3 and 
NLGN4, also clearly demonstrate the importance of de novo mutations in Autism. Jamain et 
al. found a single nucleotide insertion in two affected brothers, one with typical autism and 
the other with Asperger that arose de novo in the mother (Jamain et al., 2003). The NRXN1 
gene has also been found to harbour de novo pathogenic mutations in persons with Autism, 
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as well as in intellectual disabilities and in schizophrenia (Ching et al., 2010). Ching et al. 
found twelve deletions in NRXN1 in patients with Autism and four were de novo copy 
number variations not identified in either parent (Ching et al., 2010). SYNGAP1 (Hamdan et 
al.) and IL1RAPL1 (Piton et al., 2008) are two other examples where we found de novo 
mutations in individuals with Autism and/or intellectual disability. Actually, de novo 
mutations are also a common cause of intellectual disability (Hamdan et al.; Vissers et al., 
2010). As expected and as recently observed in Autism, de novo mutations have all been 
identified in different genes. For example, our group found six de novo deleterious mutations 
in females individuals with intellectual disability in SYNGAP1 gene (encoding synaptic Ras 
GTPase activating protein 1) (Hamdan et al.; Piton et al., 2008; Hamdan et al., 2009).  
In our recent study on the direct measurement of the de novo mutation rate in Autism and 
schizophrenia, we found a significant excess of potentially deleterious de novo mutations in 
individuals with Autism and schizophrenia (Awadalla et al., 2010). In this study, we 
examined variants identified by direct re-sequencing of 401 genes in a cohort of 285 autistic 
or schizophrenic individuals and for a subset of these genes in population control 
individuals. For the analysis, we distinguished functional from non-functional sites based 
on the effect of a mutation on the transcription or translation of the protein at a given 
position. Among trios3 without family history of Autism, we observed a significant 
enrichment of functional de novo mutations (p = 0.003 in one-tail binomial test; p = 0.022 
Fisher’s exact test). Using a binomial test, our observed number of missense to nonsense de 
novo mutations was also significantly higher than the neutral expectation (p = 0.04), 
suggesting that some of the mutations are likely to be pathogenic. All of our reported 
observations suggest an excess of potentially disease-predisposing de novo mutations in the 
Autism and schizophrenia cohorts. Indeed, in this study, from sequencing only 8% of genes 
of the human genome, functional de novo mutations were found in 5% of individuals with no 
family history of Autism, exhibiting a wide range of clinical phenotypes. These few 
examples and many others recently published collectively provide strong evidence for a 
major role of de novo mutations in Autism. 
5. Altered synaptic connectivity in autism  
The synapse is the locus of neural communication which is critical for human brain function. 
Defects in synaptic transmission are thought to underlie many common developmental 
brain disorders that are characterized by grossly normal brain structure (Zoghbi, 2003; 
Levitt et al., 2004). At a cellular level, there are presynaptic nerve endings specialized for the 
activity-dependent release of transmitter into the synaptic cleft, which is encapsulated by 
glial cells and contains adhesive molecules that keep presynaptic endings in register with 
postsynaptic specializations (“densities”) on neural cell bodies and branches. In the mature 
nervous system these structures signal by chemical transmission and thus integrate and 
propagate the electrical signals that communicate through the brain. Synapses are thought 
to form in the embryo largely by genetically pre-programmed, activity-independent and 
evolutionarily conserved mechanisms (Goodman & Shatz, 1993). During post-natal 
development, which is the period during which many developmental brain diseases start to 
manifest themselves, synaptic activity is required to select, refine and stabilize mature 
connectivity patterns (Katz & Shatz, 1996). Thus cells that fire together wire together.  
                                                 
3 A trio constitutes an affected individual and both his/her biological parents 
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Multiple indirect lines of evidence support the hypothesis of altered synaptic connectivity in 
Autism. These come in part from brain-imaging and neuropathological studies showing 
numerous alterations to both gross and microscopic structures of the brain of autistic 
individuals. For instance, an increased brain volume (Piven et al., 1996), increased brain 
weight (Bailey et al., 1998), abnormal neuronal morphology, with decreased complexity of 
dendritic branching and underdeveloped neuronal arbors (Bauman & Kemper, 1985; 
Raymond et al., 1996) have all been observed in autistic individuals. An abnormal neuronal 
density in the cerebellar hemispheres has also been observed (Bauman & Kemper, 1985). 
Notably, several components of the limbic system, including the amygdala (Lotspeich & 
Ciaranello, 1993) and the hippocampus (Raymond et al., 1996), have been found to be 
abnormal at the microscopic level.  Cytoarchitectural features that are frequently abnormal 
include reduced numbers of Purkinje neurons in the cerebellum and vermis and small 
tightly packed neurons in regions of the limbic system, especially in the entorhinal cortex 
and in the medially placed nuclei of the amygdala. The reduced neuronal size and 
shortened dendritic pattern found in post-mortem studies are consistent with synaptic 
alterations. This synaptic deficiency hypothesis has been also proposed for schizophrenia, a 
neurodevelopmental disorder that is also characterized by marked disruptions of 
information processing and cognition (Glantz & Lewis, 2000). More recently, in an effort to 
directly determine if spine densities, or the synaptic connectivity, are altered in autistic 
subjects, Hussler and Zhang examined the structural microcircuitry within the cerebral 
cortex i.e. dendritic spine densities on cortical pyramidal cells from autistic subjects and age-
matched control cases, on neurons located within both the superficial and deep cortical 
layers of frontal (BA 9), temporal (BA 21), and parietal lobe (BA 7). They observed several 
alterations in spine density in autistic subjects; for example the average spine densities in 
Autism were higher than those found in control cases, supporting altered synaptic 
connectivity and plasticity in the brains of individuals affected with Autism (Hutsler & 
Zhang, 2009).  
Other evidence suggesting impaired synaptic function in autistic individuals includes the 
discovery of mutations in different synaptic genes, such as the neuroligins, the neurexins 
and SHANK3 (see examples below in section 5.1).  As mentioned earlier, Rett syndrome 
shares many features with Autism. Mutations in the coding region of the MECP2 gene (a 
transcription repressor factor expressed by neurons and preferentially abundant in mature 
neurons) are known to be implicated in this severe disorder, with the vast majority of cases 
resulting from new mutations. Mutations in MECP2 gene have also been identified in 3 
females who meet the full diagnostic criteria for Autism, underscoring the similarity of these 
diseases (Carney et al., 2003). While the target genes for MECP2 protein remain unknown, 
the small brain size and the reduced neuronal and dendrite sizes in Rett Syndrome patients 
suggest that MECP2 may play a role in synaptic processes (Shahbazian et al., 2002; Balmer et 
al., 2003). Recent findings using the olfactory system as a model to study MECP2 expression 
during development suggest that it may be involved in the formation of synaptic contacts 
(Cohen et al., 2003). These data further support the possibility that Autism results mainly 
from synaptic dysfunction. 
5.1 Synaptic genes as candidates for autism 
At a molecular level, synapses are organized as macromolecular “machines” (Grant, 2003). 
These synaptic machines consist of a presynaptic release apparatus and a signalling device 
at the postsynaptic density held together in quasi-crystalline registry at the adhesive cleft. 
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Many of the proteins constituting these various components have been identified by 
decades of synaptic biochemistry and physiological genetics, and their macromolecular 
assemblies have been characterized by proteomic analysis. The presynaptic release 
apparatus consists of proteins that include those for the structural cytoskeleton, vesicular 
membrane and trafficking components, vesicle fusion grid and nerve terminal membrane 
(Phillips et al., 2001; Blondeau et al., 2004). The postsynaptic density consists of structural 
proteins as well as signalling components such as tyrosine kinases and phosphatases, while 
both pre- and post-synaptic membranes contain fast voltage-gated channels and 
neurotransmitter-gated receptors, channels, transporters and G-protein coupled receptors 
mediating neuromodulation (Walikonis et al., 2000; Satoh et al., 2002)  Rapid and selective 
communication across the synapse is ensured by the firm adhesion of each compartment at 
the cleft by cell surface as well as secreted extracellular matrix components (Huber et al., 
2003). It is therefore not surprising that synaptic genes constitute the largest class of genes 
associated to developmental brain disorders – with many more to be discovered.  Likewise, 
since many of these proteins are exposed at the extracellular surface, they could provide 
excellent “druggable” targets. 
The discovery of genes clinically relevant to Autism is accelerating, with many involved in 
the synapse including several neuroligands, as well as genes involved in the glutamatergic 
pathway (Betancur et al., 2009). Of particular interest is the example of the synaptic cell 
adhesions and associated molecules including the neuroligins-neurexins-SHANK3 genes. 
Mutations in the X-linked neuroligin-3 (NLGN3) and neuroligin-4 (NLGN4X and NLGN4Y) 
genes have been identified in brothers with autism. Laumonnier et al. identified a two base-
pair deletion in NLGN4 in 12 affected members of a French family with X-linked mental 
retardation, some of whom were also autistic (Laumonnier et al., 2004). Jamain et al. 
identified a C-to-T transition in the NLGN3 gene, in two brothers, one with autism and the 
other with Asperger syndrome (Jamain et al., 2003). The SHANK3 gene, which codes for a 
synaptic protein that binds directly to neuroligins, seems crucial for the development of 
language and social cognition. SHANK3 mutations and small cytogenetic rearrangements 
have been implicated with the Autism phenotype (Durand et al., 2007; Gauthier et al., 2009). 
Other genes involved in this pathway have been found to be mutated in autistic individuals. 
Indeed, variants in SHANK2 and LRRTM1 are reported in schizophrenia and Autism 
(Francks et al., 2007; Berkel et al., 2010). Other synaptic molecules implicated in Autism are 
the protocadherin family genes, which have been shown to be associated with Autism. 
Marshall et al. detected causative copy number variations in PCDH9 gene and a de novo 
translocation deleting the CDH18 genes in Autism (Marshall et al., 2008). Moreover, in a 
study of consanguineous families of Autism, a large homozygous deletion implicating 
PCDH10 was detected (Morrow et al., 2008). All of these examples emphasized the role of 
impaired synaptic pathways in the pathogenesis of Autism. 
6. Similar genetic architecture in other neurodevelopmental disorders  
Autism, schizophrenia, and intellectual disability are all severe neurodevelopmental 
disorders that have childhood or early adulthood onset with a lifetime disability. Clinical 
manifestations of these disorders are diverse and complex, and include abnormalities in 
neuronal excitability, processing of complex information, as well as behaviors such as 
anxiety and impaired social interactions. Pathological studies, neuroimaging and other 
clinical observations predict that these disorders result from disrupted neurodevelopment 
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caused by genetic and environmental factors (Lewis & Levitt, 2002). There is a significant 
overlap in clinical manifestations in these mental disorders, such as episodic psychosis 
and/or seizures, impaired cognitive functions, and language problems. Fifteen to thirty 
percent of Autism patients present with seizures and 20% of psychotic patients were 
diagnosed as having pervasive developmental disorders (Matese et al., 1994). Also, there is 
no clear clinical or neurobiological distinction between childhood schizophrenia, pervasive 
developmental disorder and autism (Mouridsen et al., 2000). Furthermore, these 
neurodevelopmental disorders can be included within the allelic spectrum of the same 
candidate gene. These observations strongly suggest that Autism, schizophrenia and 
intellectual disability may share similar pathogenic pathways and, thus, potential candidate 
genes. In addition, Autism, schizophrenia and intellectual disability have also a high 
prevalence, a high monozygotic twin concordance, a predicted high level of allelic and non-
allelic genetic heterogeneity and a uniform worldwide high incidence despite significantly 
reduced reproductive fitness. All of these observations support the notion that the de novo 
mutations model be involved in all these disorders.  
6.1 One gene, three phenotypic conditions 
We believe that Autism, schizophrenia and intellectual disability, all severe 
neurodevelopmental disorders, can be studied in a similar manner, which focuses on the 
synaptic gene de novo mutation model. In addition, in some instances mutations in the same 
gene can lead to Autism, intellectual disability or schizophrenia, three clinically distinct 
phenotypes, as defined in the Diagnostic and Statistical Manual of Mental Disorders, the 
reference manual for the classification of mental disorders. A recent example is our findings 
with the SHANK3 gene. Disruption of this synaptic gene was originally associated with the 
22q13.3 deletion syndrome [OMIM 606232] characterized by neonatal hypotonia, global 
developmental delay, normal to accelerated growth, absent to severely delayed speech, 
autistic behavior (OMIM 209850), and minor dysmorphic features. In 2007, Durand et al. 
and Moessner et al., showed that abnormal gene dosage of SHANK3 is associated with 
Autism (Durand et al., 2007; Moessner et al., 2007). In addition, we identified a de novo 
splicing mutation in SHANK3 in a patient with non-syndromic intellectual disability 
without Autism (Hamdan et al.). We also found deleterious de novo mutations in the 
SHANK3 gene in a patient diagnosed with schizophrenia plus cognitive impairment. 
Similarly, mutations in the NRXN1 gene can lead to rare forms of Autism and schizophrenia 
(Kim et al., 2008; Rujescu et al., 2009). This phenomenon has been observed in other diseases 
and, as stressed by Zoghbi and Warren in their recent paper (Zoghbi & Warren, 2010), other 
examples include the ARX gene which causes X-linked lissencephaly, agenesis of corpus 
callosum with abnormal genitalia, cognitive deficits with or without seizures, or cognitive 
deficits, dystonia, and seizures; LMNA gene, which can lead to a diversity of disorders 
including Emery-Dreifuss muscular dystrophy Type 2, Charcot-Marie-Tooth axonal 
neuropathy limb girdle muscular dystrophy Type 1B, Hutchinson-Gilford progeria 
syndrome, and many other different clinical manifestations. 
Altogether, these findings suggest that the neuroanatomical and physiological disturbances 
resulting from dysfunction of mutant genes may be influenced by the effect of genetic 
modifiers, the nature of the gene’s role in the human brain and the effect of environmental 
experiences of the affected individuals, leading to different clinical outcomes in different 
patients. Differences in the mutation types (for example, point mutation vs. large gene 
disruptions) must certainly also contribute to the phenotypic variability. Although this 
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observation is intriguing, multiple phenotypic manifestations from mutations of the same 
single gene have been described for many other diseases. Finally, the observation that one 
gene can lead to many phenotypes raised the question of whether Autism, schizophrenia 
and intellectual disability are different entities or part of a same phenotypic continuum.  
7. Gene hunting approaches and the impact of the development of new 
technologies   
In the last few years, a new generation of technologies, referred to as the next-generation 
DNA sequencing technologies have been developed which allow screening of the entire 
genome (i.e. > 20,000 genes) of single individuals within a matter of days. This new 
technology has revolutionized genetic research and has allowed new approaches in the 
search for diseases-causative genes. Before the advent of the next-generation DNA 
sequencing technologies, gene screening for the identification of disease-causative mutation 
was done one gene at a time. Next-generation DNA sequencing enable the parallel 
sequencing of all the 20,000 genes, leading to faster identification of mutations.  These 
technologies therefore constitute the ideal method of screening for rare causative variants in 
all genes simultaneously. In the context of Autism and of the above mentioned de novo 
mutation genetic mechanism, the major advantage of these technologies is to make possible 
the identification of very rare de novo mutations, by comparing the genetic variants in an 
affected subject to those in both of his/her parents (a family trio). Given sufficient coverage 
and quality in next-generation DNA sequencing datasets, identifying de novo mutations in 
trios is highly feasible.   
Sequencing of entire genomes is still rather expensive, so many groups now focus on the 
sequencing of the entire “exome” (i.e., the various coding regions of the genome) of an 
individual. Focusing on the exome is a reasonable approach as the vast majority of disease-
causing mutations identified to date disrupt the protein-coding regions of genes. Such 
mutations include nonsense, small insertion/deletions, frameshifts, splicing and missense 
mutations, whose consequences can be predicted in silico based on well-annotated reference 
datasets (e.g. the human consensus CDS (CCDS) subset of the NCBI RefSeq database 
includes 23,339 consistently annotated protein-coding transcripts).  These coding regions 
constitute less than 3% of the entire genome. Oligonucleotide hybridization-based methods 
that permit the capture and amplification of virtually all human exons at once, i.e. the 
human “exome”, are now commercially available (NimbleGen, Agilent, Illumina). Limiting 
the analysis to the exome significantly increases the number of samples that can be 
sequenced, and is more likely to identify causative genes. Since it is likely that highly 
penetrant alleles (i.e. protein-truncating or missense) in different autistic cases will result 
from mutations in dozens of different genes,  it is preferable to concentrate on re-sequencing 
only the coding regions of the genome, or the “exome”,  using targeted microarray capture 
followed by next generation sequencing. In addition mutations in coding regions are most 
easily interpreted thus making the link to the disorder easier to establish. The availability of 
these technologies is accelerating all aspects of the gene hunting process e.g. increasing 
number of genes that can be now analysed in a shorter period of time and the number of 
subjects being studied.  
7.1 Challenges for the next-generation approaches 
As next-generation DNA sequencing technologies improve, and as it becomes possible to 
rapidly produce detailed lists of variants per individual genome, the challenge will be to 
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discriminate the pathogenic variants from the benign ones and establish the link to the 
disorder. Three major challenges can be identified. The first and most technical one is the 
ability to handle very large datasets in the order of tens or hundreds of terabytes in size, and 
access to powerful computing platforms that can process these datasets, and adequate 
resources for storage, retrieval and archiving. The second is the capacity to develop robust 
yet comprehensive methods to identify variants from next-generation DNA sequencing 
datasets. Choosing the correct sequence coverage and quality filters will ensure a maximum 
of true variants to be identified, with as few false positives or false negatives as possible. 
Several programs are available that can align short sequence reads to a reference genomic 
sequence and call potential homozygous or heterozygous variants. However, the total 
number of variants identified, even using different parameters within the same program, 
can vary largely.  Intuitive paradigms and empirically determined cut off points need to be 
implemented. Furthermore, the accurate annotation of genomic variants is critical to 
classifying different variants for their potential impact on transcription, splicing or 
translation. This step must be comprehensive so that potential protein-truncating variants 
are not missed given that alternate splicing can lead to different transcripts with different 
open reading frames within a single gene. Finally, developing an experimental design based 
on the known or anticipated genetic mechanisms underlying the disease or condition, and 
on high quality diagnostic procedures, requires that affected and unaffected individuals be 
carefully selected from family groups to help prioritize variants for further analysis, and to 
maximize the chances of finding causative genes. In our case, identifying de novo mutations 
by analysing trios can very quickly lead to the identification of causative mutations and risk 
genes.  Successful mastery of these key strategic and technical competencies is necessary to 
identify potentially pathogenic variants. 
7.2 Copy number variations and autism 
The use of microarray approaches for the detection of copy number variations, which its 
continuously improving resolution, provides additional evidence for the occurrence of de 
novo genomic events in the pathogenesis of Autism. In the last decade, studies  linking copy 
number variation, and Autism have revealed that de novo and inherited copy number 
variations, including deletions and duplications, translocations, and inversions of 
chromosomes, all may significantly contribute to the pathogenesis of Autism, usually as 
penetrant rare variants (Sebat et al., 2007; Walsh et al., 2008). For example Sebat et al.  
showed that de novo copy number variations are more common in autistic patients than in 
non-autistic individuals (Sebat et al., 2007). They found that 10% of their patients with 
sporadic Autism (i.e. individuals with no history of the disorder) harboured a de novo copy 
number variation, while the frequency was only 3 % in patients with an affected first-degree 
relative and 1% in controls.  
Other similar examples include the study from Marshall et al. (Marshall et al., 2008), 
Christian et al. (Christian et al., 2008) and Szatmari et al. (Szatmari et al., 2007) and more 
recently the report of Bremer et al. (Bremer et al.), which are all consistent with the 
hypothesis that de novo or weakly recurrent copy number variations seem to be significant 
contributing factor in the pathogenesis of Autism.  Interestingly, based on the results of their 
copy number variations analyses, Marshall et al, concluded that “structural de novo were 
found in sufficiently high frequency in Autism subjects suggesting that cytogenetic and 
microarray analyses be considered in routine clinical workup” (Marshall et al., 2008). 
Although this is not the focus of this chapter, the genes identified by copy number variation 
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analysis also support the notion that there are shared biological pathways in Autism, 
intellectual disability and schizophrenia (Guilmatre et al., 2009)  
8. Conclusion and directions for future studies  
As outlined throughout this chapter, several lines of evidence support the role of de novo 
mutations in the pathogenesis of Autism. De novo mutations are a well-established genetic 
mechanism for the development of a number of disorders such as Rett Syndrome and 
certain types of cancers but have been poorly explored for common diseases like Autism. In 
general, the development of technologies often brings new challenges, but mostly allows 
research to accelerate. Indeed, this technological progress is already starting to provide data 
supporting the role of de novo mutations in Autism. This hypothesis is gaining acceptance in 
the scientific community, as reflected in the growing number of recent publications on this 
subject. Although the focus of this chapter is on the role of de novo mutations in Autism, we 
acknowledge the fact that many other genetic or non-genetic mechanisms certainly 
contribute to this disorder.  
The accessibility of next-generation DNA sequencing methodologies have enabled 
researchers to analyse a large amount of DNA and has had an important impact on gene 
hunting strategies , which have shifted from a tendency to look at single genes, one at the 
time, to multiple genes simultaneously. One interesting consequence of next-generation 
DNA sequencing is that it recently permitted to directly estimate the rate of de novo germline 
base substitution mutations in humans (Awadalla et al., 2010; Durbin et al., 2010). Based on 
these data, the challenge will be to determine if the observed de novo mutation rate detected 
in a disease is greater than the baseline rate.  
In the last few years, researchers have identified several genes contributing to Autism, and 
most encode for proteins that are part of the synaptic machinery. An important concern for 
future research, where there will be rapid identification of many potential Autism gene 
mutations, will be to determine if they have a functional relevance to the disorder. Indeed, 
this question needs to be judiciously examined for most of the variants discovered. This will 
require to study  model organism systems as proposed in our current Synapse to disease 
project (S2D; http://www.synapse2disease.ca), a large-scale medical research project 
launched in 2006 aiming to identify genes involved in several neurological and psychiatric 
diseases caused by defects in the development and functioning of the brain and nervous 
system. This project’s philosophy is that once the base changes are discovered and 
considered  likely to be  “pathogenic mutations”, biological validation must be conducted in 
vitro and in vivo in different model organism (e.g. fly, worm, fish, etc.) to determine their 
functional effects. Biological validation is an essential step often missing from most genetic 
studies and has thus severely limited data interpretation in the context of disease pathology. 
This validation will consequently help understanding pathways in neurodevelopmental 
disorders and ultimately give insights for the development of targeted therapeutic 
strategies.  
Another challenge for future research in the field is the issue of whether genomic variants 
beyond the coding regions of a gene contribute to the etiology of the disorder. As mentioned 
earlier, the majority of mutations identified in Autism are located within coding regions but 
it should not be forgotten that variants in the non-coding regions, particularly the regulatory 
gene region, can also lead to disease.  
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Finally, the accessibility of the next-generation DNA sequencing technologies is facilitating 
the gene hunting process for researchers, whereas its application for clinical diagnostic 
testing seems to be inevitable, particularly as the cost per base continues to decrease.  
Although, the clinical tests based on these technologies represent particular challenges and 
will need careful validation, the connection between research findings in the genetics of 
Autism or any other neurodevelopmental disorders and clinical applications is closer than 
ever. All these research and technological advancements are for the greatest benefit of 
families. 
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